Application and Diagnostic Performance of Two-Dimensional Shear Wave Elastography and Liver Fibrosis Scores in Adults with Class 3 Obesity

Abstract

There are no ideal non-invasive tests for assessing the severity of liver fibrosis in people with metabolic dysfunction-associated steatotic liver disease (MASLD) and class 3 obesity, where body habitus often makes imaging technically challenging. This study aimed to assess the applicability and diagnostic performance of two-dimensional shear wave elastography (2D-SWE), alongside several serum-based liver fibrosis scoring methods, in individuals with class 3 obesity. A cross-sectional study was conducted in patients aged ≥18 years and with a body mass index (BMI) ≥ 40 kg/m2 who were participants in a publicly funded multidisciplinary weight management program in South Western Sydney. The 2D-SWE was performed using the ElastQ Imaging (EQI) procedure with the Phillips EPIQ Elite series ultrasound. An EQI Median value of ≥6.43 kPa was taken as a cutoff score for significant fibrosis, and the scan was considered valid when the liver EQI IQR/Med value was <30%. The Fibrosis-4 (FIB-4) index, AST-to-platelet ratio index (APRI), NAFLD fibrosis score (NFS), and circulating fibroblast activation protein index (FAP index) were calculated from fasting blood samples. The participants (n = 116; 67.2% female) were aged 47.2 ± 12.9 years, with BMI 54.5 ± 11.0 kg/m2. EQI Median values were obtained for 97.4% (113/116) of the 2D-SWE scans, and 91.4% (106/116) of the scans were considered valid. The EQI Median values exhibited a moderately positive correlation with the FIB-4 index (r = 0.438; p < 0.001) and a weakly positive correlation with the APRI (r = 0.388; p < 0.001), NFS (r = 0.210; p = 0.036) and FAP index (r = 0.226; p = 0.020). All liver fibrosis scores were positively correlated with one another. Among those referred for a liver biopsy based on the 2D-SWE and serum scores, half (11/22) underwent liver biopsy, and their 2D-SWE scores exhibited 72.7% accuracy (sensitivity: 71.4%; specificity: 75%) in detecting significant fibrosis. Our results show that 2D-SWE is a feasible, non-invasive test to assess liver fibrosis among people with class 3 obesity. Further research is needed to assess how 2D-SWE can be used alongside existing serum-based risk scores to reliably detect significant fibrosis, which would potentially reduce the need for invasive liver biopsy.

Remote Delivery of Partial Meal Replacement for Weight Loss in People Awaiting Arthroplasty

“…This is a prospective pilot cohort study where participants were recruited from a waiting list of people awaiting TKA or THA in a high-volume (~600 procedures per year pre-COVID-19) public arthroplasty centre in Sydney, Australia. This study was conducted between January 2022 and August 2022, and the intervention was delivered remotely via telehealth due to COVID-19 restrictions and supported by a team of dietitians with access, if required, to a previously described publicly funded multidisciplinary weight management program [ 32 , 33 , 34 , 35 ]. All eligible participants were invited to participate in this study and only those who provided informed consent were included.…”

Predictors of Mental Health Outcomes in a Multidisciplinary Weight Management Program for Class 3 Obesity

“…Referrals to the WMP could be made by any medical practitioner, and the multidisciplinary team included endocrinologists, dietitians, psychologists, physiotherapists, a gastroenterologist, a psychiatrist, and a specialist nurse. Each component of the WMP and the cohort study has been previously published [15,[50][51][52][53]. The team provided care individually tailored to each patient, which included one or more of the following: lifestyle interventions, behavioural modifications, dietary interventions, and pharmacotherapy.…”